TABLE 2.
AEs observed in each group*.
| SCs group (n = 18) | Tofacitinib group (n = 20)a, c | Combined group (n = 23)c | |
| Patients who experienced AEs, n(%) | 12 (66.7%) | 7 (35.0%) | 13 (56.5%) |
| Infections (n) | Acne (3) | Acneiform eruption (4)b | Folliculitis (4) |
| Zoster (1) | Acneiform eruption (6)b | ||
| Wart (1) | |||
| Upper respiratory infection (2) | |||
| Other AEs (n) | Weight gain (8) | Fatigue (1) | Liver enzyme abnormalities (2) |
| Moon facies (2) | Hyperlipidemia (2) | Hyperlipidemia (2) | |
| Arthralgia (1) | Arthralgia (1) | Hirsutism (3) | |
| Hirsutism (1) | Weight gain (5) | ||
| Headache (1) | Proteinuria (1) | ||
| Menstrual irregularity (1) | Fatigue (1) | ||
| Hypertension (1) | Moon facies (1) | ||
| Sleep disturbance (1) | Menstrual irregularity (1) | ||
| Frequent urination (1) |
*The proportions of patients who experienced AEs were not significantly different between the three groups (P = 0.132).
aOne patient was diagnosed with asymptomatic liver enzyme elevation before treatment, which didn’t increase during the therapy.
bPatients who experienced acneiform eruption mostly performed as whitehead.
cTwo patients in the combined group and the tofacitinib group were diagnosed with hepatitis before the treatment. Both of them experienced elevated HBV DNA during the treatment without any liver enzyme abnormalities and liver symptoms, one of whom is taking anti-virus medication for now.
SCs, systemic corticosteroids; AEs, adverse effects.